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Interactome
Lipid raftsFibroblast activation protein alpha (FAPα) is a cell surface protease expressed by cancer-associated ﬁbroblasts in
the microenvironment of most solid tumors. As there is increasing evidence for proteases having non-catalytic
functions, we determined the FAPα interactome in cancer-associatedﬁbroblasts using the quantitative immuno-
precipitation combined with knockdown (QUICK) method. Complex formation with adenosin deaminase, erlin-
2, stomatin, prohibitin, Thy-1 membrane glycoprotein, and caveolin-1 was further validated by immunoblotting.
Co-immunoprecipitation (co-IP) of the known stoichiometric FAPα binding partner dipeptidyl-peptidase IV
(DPPIV) corroborated the proteomic strategy. Reverse co-IPs validated the FAPα interaction with caveolin-1,
erlin-2, and stomatin while co-IP upon RNA-interference mediated knock-down of DPPIV excluded adenosin de-
aminase as a direct FAPα interaction partner. Many newly identiﬁed FAPα interaction partners localize to lipid
rafts, including caveolin-1, a widely-used marker for lipid raft localization. We hypothesized that this indicates
a recruitment of FAPα to lipid raft structures. In density gradient centrifugation, FAPα co-fractionates with
caveolin-1. Immunoﬂuorescence optical sectioning microscopy of FAPα and lipid raft markers further corrobo-
rates recruitment of FAPα to lipid rafts and invadopodia. FAPα is therefore an integral component of stromal
lipid rafts in solid tumors. In essence, we provide one of the ﬁrst interactome analyses of a cell surface protease
and translate these results into novel biological aspects of a marker protein for cancer-associated ﬁbroblasts.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Epithelial tumors are typically embedded in a reactive stroma,which
is thought to have a key role in disease progression. Emerging evidence
suggests that cancer-associated ﬁbroblasts (CAFs), a highly abundant
cell type in the stroma ofmany solid tumors, contribute to invasiveness,
metastasis formation, and resistance to therapy [1]. Fibroblast activated
protein alpha (FAPα) is a marker protein for CAFs [2]. FAPα expression
is reported for 90% of epithelial tumors [3]. FAPα is further expressed
during embryogenesis,wound healing, andﬁbrosis aswell as bymesen-
chymal stem cells [4]. The restricted, largely tumor-speciﬁc expression
proﬁle in adults has raised substantial interest into its pharmacological
targeting [4].associatedﬁbroblast; CBM, cav-
ha; Fc, fold change; LC-MS/MS,
immunoprecipitation; QUICK,
down; Thy-1, Thy-1 membrane
04 Freiburg, Germany.
.de (O. Schilling).FAPα acts as both an aminodipeptidase (preferentially cleaving
post-proline) and, to a smaller extent, an endopeptidasewith a speciﬁc-
ity for Gly-Pro motifs. FAPα is a 170 kDa homodimer that contains two
N-glycosylated 97 kDa subunits. The FAPαmonomers are type II inte-
gral membrane proteins with a large C-terminal extracellular domain
and a short, single membrane-spanning domain. The crystal structure
of the ectodomain has been solved [5]: close to the membrane-
spanning domain is a β-propeller domain followed by an α/β-
hydrolase domain. The catalytic triad is located between the interfaces
of these two domains.
FAPα expressing CAFs support tumor progression by potentiating
tumor growth, stimulating angiogenesis, and reshaping the extracellu-
lar matrix [6]. Despite numerous ﬁndings of FAPα expression in various
cancerous tissues, little is known about the role of FAPα in the tumor
microenvironment [4]. Direct coculture of primary human breast cancer
cells with ﬁbroblasts expressing FAPα showed increased epithelial–
mesenchymal transition (EMT) and faster migration than did cancer
cells co-cultured with FAPα negative ﬁbroblasts isolated from the
same tumor [7]. In specimens of human colon cancer patients it was
shown that FAPα expression correlates with metastatic burden [8].
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pletion of FAPα expressing cells resulted in hypoxic necrosis of tumor
and stromal cells in a transgenic mousemodel [9]. An angiogenesis pro-
moting role in the tumor microenvironment was also shown for FAPα
[10,11]. Yet there is also some evidence for a tumor suppressive role
of FAPα [12,13].
It remains elusive how FAPα exerts thismultiple functions involving
a variety of different downstream pathways. A small number of FAPα
substrates have been identiﬁed [4]. At the same time, there is increasing
evidence that proteases may exert their biological function in a
non-enzymatic manner. Examples include involvement of matrix
metalloproteases in cellular migration [14] and non-enzymatic func-
tions of the cell surface serine protease prostasin [15,16]. Such observa-
tions make it essential to elucidate protease interactomes in order to
better understand the molecular basis of their in vivo functions.
In the present study on FAPα, we provide one of the ﬁrst proteomic
interactome analyses for a proteolytic enzyme. FAPα is known to form
heterodimers with the related protease DPPIV [17]. To gain further in-
sight in the FAPα interactome we performed a proteomic interaction
screen by quantitative immunoprecipitation combined with knock-
down (QUICK) [18]. QUICK combines metabolic stable isotope labeling
(SILAC), RNA interference (RNAi)mediated knock-downof the bait pro-
tein for control purposes, co-immunoprecipitation, and quantitative
mass-spectrometry analysis to detect cellular interaction partners at en-
dogenous concentration levels. Our study identiﬁes a new link between
FAPα and caveolin-1, which forms an integral part of lipid rafts. Based
on this ﬁnding we further demonstrate lipid raft localization of FAPα.
In essence,we present oneof theﬁrst interactomeanalyses of a protease
and highlight translation of interactome data into cell biological
ﬁndings.
2. Material and methods
2.1. CAF cell culture and viral transduction
Telomerase-immortalized human colon cancer-associated ﬁbro-
blasts (CAFs) were described previously [19]. Cells were cultured in
Dulbecco's modiﬁed Eagle's medium (DMEM, PAN, Aidenbach,
Germany) supplemented with 10% fetal calf serum (PAN, Aidenbach,
Germany) and 1% penicillin/streptomycin stock solution (Gibco/
Invitrogen, Paisley, UK) at 37 °C in humidiﬁed air containing 5% CO2.
2.2. shRNA expressing lentiviral vectors and viral production
Stable knockdown of human FAPαwas generated by viral transfec-
tion with the short hairpin (sh) RNA expressing vector pLKO.1-neo
(Soneoka et al., 1995). pLKO.1-neo was derived from pLKO.1-puro
(pMISSION system, SIGMA-Aldrich, Schnelldorf, Germany) by replacing
the puromycine resistance cassette with a neomycine resistance cas-
sette. The CT5.3shFAP and the CT5.3 shctrl cell line were generated by
transfecting CT5.3 cells with the vector pLKO.1-neo either containing
the shRNA sequence CCGGGCATTGTCTTACGCCCTTCAACTCGAGTTGAA
GGGCGTAAGA CAATGCTTTT or the scrambled shRNA sequence CCGG
CAACAAGATGAAGAGCACCAATTTTT, respectively.
2.3. QUICK screen in CT5.3 cells
Endogenous FAPα interaction partners were identiﬁed from CT5.3
cells by using the QUICK approach. SILAC labeling and assay procedures
were performed essentially as described [18]. CT5.3 cells transduced
with either control or FAPα targeting shRNA were grown at least ﬁve
passages in DMEM without arginine and lysine (Silantes, Munich,
Germany) supplemented with 10% dialyzed fetal calf serum (Silantes,
Munich, Germany) and supplemented with either normal lysine and
arginine or the heavy isotope labeled counterparts (arginine: 13C615N5;
lysine: 13C6) (Silantes, Munich, Germany).CT5.3 cells grown in ﬁve 15 cm dishes per condition were washed
twice with 5 ml DPBS (PAN-Biotech, Aidenbach, Germany) and lysed
in 1 ml ice-cold lysis buffer (50 mM Tris, pH 7.5, 75 mM NaCl, 0.5%
Nonidet P-40, 1 × Roche complete protease inhibitor mixture (Roche,
Mannheim, Germany)) per plate by on-plate lysis. Lysates were kept
on ice for 30 min with intermittent inverting to ensure proper lysis.
Lysates were centrifuged for 10 min at 16,600 ×g and 4 °C. Protein
concentration of lysates was determined using the BCA method
(ThermoScientiﬁc, Rockford, USA). 10 mg of protein per condition in
equal volume was incubated with 20 μg anti-FAPα antibody for 3 h at
4 °C with rotation. 60 μl of dynabeads protein G (Life Technologies,
Darmstadt, Germany) per condition was added and lysates were incu-
bated for an additional hour at 4 °C with rotation. The dynabeads
were washed three times with washing buffer (50 mM Tris, pH 7.5,
75 mM NaCl, 0.5% Nonidet P-40) and the matrices of the two separate
immunoprecipitations were combined. Protein complexes were eluted
in elution buffer (50 mM Tris, pH 7.5, 75 mM NaCl, 0.5% Nonidet P-40)
and 1 × NuPage buffer (Invitrogen, Carlsbad, USA) for 5 min at 95 °C
and 300 rpm. Protein containing supernatant was removed from the
beads. The supernatant was reduced using 10 mM DTT (AppliChem
GmbH, Darmstadt, Germany) for 10 min at 95 °C and alkylated using
20 mM iodoacetamide (Sigma-Aldrich, Schnelldorf, Germany) for
30 min at RT. Protein mixtures were separated by SDS-PAGE using 4–
12% Bis-Tris mini gradient gels (Invitrogen, Carlsbad, USA). The gel
lane was cut into eight slices, which were in-gel digested with trypsin
(Promega, Madison, USA) [19]. The resulting peptide mixtures were
desalted on self-packed C18 STAGE tips (Empore, St. Paul, MN, USA)
[20] and subjected to liquid chromatography-tandemmass spectrome-
try (LC-MS/MS) analysis.
2.4. LC-MS/MS analysis and data processing
For nanoﬂow-LC-MS/MS analysis, samples were analyzed on a Q-
Exactive plus (Thermo Scientiﬁc GmbH) mass spectrometer coupled to
an Easy nanoLC 1000 (Thermo Scientiﬁc) with a ﬂow rate of 300 nl/min
each. Buffer A was 0.5% formic acid, and buffer B was 0.5% formic acid
in 100% acetonitrile (water and acetonitrile were at least HPLC gradient
grade quality). A gradient of increasing organic proportionwas used for
peptide separation (5–40% acetonitrile in 80 min). The analytical col-
umnwas an Acclaim PepMap column (Thermo Scientiﬁc), 2 μmparticle
sizes, 100 Å pore sizes, length 150 mm, I.D. 50 μM. The mass spectrom-
eter operated in data dependent mode with a top 10 method at a mass
range of 300–2000.
LC-MS/MS data in raw format was converted to the mzXML [21]
format, using msconvert [22] with centroiding of MS1 and MS2 data,
and deisotoping of MS2 data. For spectrum to sequence assignment X!
Tandem (Version 2013.09.01) [23] was used. The proteome database
consisted of human reviewed canonical uniprot sequences (without
isoforms) downloaded fromUniProt onNovember 26, 2013. It consisted
of 20,240 real protein entries. It was appendedwith an equal number of
shufﬂed decoy entries derived from the original human protein se-
quences. The decoy sequences were generated with the software DB
toolkit [24]. X! Tandem parameters included: pre-cursor mass error of
±10 ppm, fragment ion mass tolerance of 20 ppm, tryptic speciﬁcity
with up to one missed cleavage, static residue modiﬁcations: cysteine
carboxyamidomethylation (+57.02 Da), variable modiﬁcations were
isotope-labeled (+6.02 Da) arginine and lysine.
X!Tandem results were further validated by PeptideProphet [25].
The ProteinProphet algorithm [26] at a false discovery rate of less than
1%, was used for protein identiﬁcation. For relative peptide and protein
quantiﬁcation, XPRESS [27] was used. Mass tolerance for quantiﬁcation
was 0.015Da. Ratios of each datasetwere calculated as FAPα expression
(shRNA control) over FAPα knockdown. XPRESS data was log2-
transformed yielding fold-change (Fc-)values. A total of ﬁve replicate
QUICK experiments were performed, including a label-switch experi-
ment, in which the shRNA control cells were labeled light and the
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FAPα interaction partners if they were identiﬁed and enriched in at
least four of ﬁve replicate FAPα co-immunoprecipitation experiments
with joint analysis showing a signiﬁcant (p-value b 0.01, two-sided T-
Test) quantitative enrichment in the immunoprecipitates with a more
than 2-fold (Fc-value N 1) average enrichment.
2.5. Western blot analysis
Immunoprecipitation of proteins for Western Blot analysis was
performed under the same conditions as for the QUICK screen with
the exception of a different elution procedure. ForWestern Blot analysis
proteinswere eluted in Laemmli buffer (50mMTris, pH 6.8, 1% SDS, 10%
glycerol, 10mMDTT, bromphenol blue) for 5min at 95 °C and 300 rpm.
Immunoprecipitated proteins or 10% of input cell lysates were loaded
on 12.5% SDS-polyacrylamide gels. After electrophoretic separation pro-
teins were transferred on polyvinylidene ﬂuoride (PVDF) membranes
using a semidry blot system (BioRad, Munich, Germany). After blocking
with 3% BSA in PBS-T the membranes were incubated with the respec-
tive primary antibodies: ADA 1:500 (Abcam, Cambridge, UK,
#ab108352), FAPα 1:500 (R&D Systems, Minneapolis, USA, #AF3715),
caveolin-1 1:1000 (ThermoScientiﬁc, Rockford, USA, #MA3-600),
DPPIV 1:500 (R&D Systems, Minneapolis, USA, #AF1180), Erlin-2
1:500 (ThermoScientiﬁc, Rockford, USA, #PA5-17103), stomatin 1:500
(Abcam, Cambridge, UK, #ab169524), Thy1 1:500 (Cell Signaling,
Danvers, USA #9798), tubulin 1:1000 (Sigma-Aldrich, Schnelldorf,
Germany, #T6199), prohibitin 1:500 (ThermoScientiﬁc, Rockford, USA,
#PA5-17325) overnight at 4 °C. After washing, themembranes were in-
cubated for 1 hwith the corresponding secondary antibody: anti-mouse
(Dianova, Hamburg, Germany #115-035-003), anti-rabbit 1:2500
(BioRad, Munich, Germany, #172-1019), anti-sheep 1:2500 (Dianova,
Hamburg, Germany, #711-035-152). The membranes were washed
and developed with theWest Pico Chemiluminescent substrate (Pierce,
Rockford, USA). Peroxidase activity was detected with the Fusion SL
device (Peqlab, Erlangen, Germany).
2.6. DPPIV knockdown
For generation of a transient DPPIV knockdown CT5.3wt cells were
grown to 50% conﬂuence. Medium was replaced by DMEMw/o antibi-
otics and 10 μM of siRNA was transfected into the cells using RNAimax
(Invitrogen, Carlsbad, USA) according to manufacturer's instructions.
siRNAwas incubated for 24 h before lysis and subsequent immunopre-
cipitationwere performed. Amixture of four siRNA constructs targeting
DPPIV was purchased from Qiagen (Hilden, Germany, # 2924986) as
well as a scrambled control siRNA (#SI03650318).
2.7. Immunoﬂuorescence
CT5.3 cells were plated on glass coverslips placed in a 24-well plate
(3× 105 cells/well) and grown for 24 h before ﬁxation in 4% paraformal-
dehyde (Thermo Scientiﬁc, Rockford, USA) in PBS for 20 min at room
temperature. For induction of invadopodia cells were treated with
100 nM Protein Kinase C activator Phorbol 12-myristate 13-acetate
(PMA) as described elsewhere [28] 1 h prior to ﬁxation.
Cover slips were washed with PBS three times for 5 min. After
blocking in PBS containing 3% BSA, 0.3 M glycine and 0.1% Tween for
90min at room temperature cells were incubated with the primary an-
tibody: FAPα 1:200 (Santa Cruz, Dallas, USA, #sc-65398), caveolin-1
1:400 (Thermo Scientiﬁc, Rockford, USA, #PA5-17447), stomatin
1:200 (Abcam, Cambridge, UK, #ab169524) in PBS supplemented with
3% BSA for 16 h at 4 °C with gentle agitation. After washing three
times for 5 min with PBS, incubation with the secondary antibody was
performed: anti-mouse 488 (Invitrogen, Carlsbad, USA, #A11001),
anti-rabbit 546 (Invitrogen, Carlsbad, USA, #A11010). For staining of
lipid raft cells were incubated with cholera toxin subunit B (CTB)Alexa Fluor 555 1:1000 (Life Technologies, Darmstadt, Germany, # C-
34776) in PBS supplemented with 3% BSA. F-actin was stained with
Rhodamine Phalloidin (Life Technologies, Darmstadt, Germany,
#R415) 1:1000 in PBS supplemented with 3% BSA parallel to secondary
antibody incubation.
Secondary antibody, CTB, and phalloidin incubationwere performed
for 1 h at room temperature with gentle agitation. Cover slips were
rinsed three times for 5 min with PBS and nuclei stained for 3 min
with 2 μg/ml Hoechst (Fluka/Sigma, Munich, Germany). After a ﬁnal
wash with PBS, cover slips were mounted with Permaﬂour (Labvision,
Fremont, USA). Microscopy images (×1000; ×100 PlnN 1.3 oil objec-
tive) were taken with an Observer.Z1 ﬂuorescence microscope (Zeiss,
Oberkochen, Germany) at 475/530 nm (λex/λem) for green ﬂuores-
cence, 530–585/615 nm for red ﬂuorescence, and 365/445–450 nm for
blue ﬂuorescence. To obtain optical sections the ApoTome.2 (Zeiss,
Oberkochen, Germany) was used. Images were obtained with an
AxioCam MRm and processed with Axio Vision software (Zeiss,
Oberkochen, Germany).
2.8. Isolation of lipid rafts
CT5.3wt cells were washed twice with PBS and harvested in PBS
supplemented with 1 × Roche complete protease inhibitor mixture
(Roche, Mannheim, Germany). Cells were pelleted and 300 μl of packed
cells were resuspended in 700 μl of ice-cold 1% Triton X-100 in HEPES-
buffered saline (25 mMHEPES, 150 mMNaCl, 1 × Roche complete pro-
tease inhibitor mixture) and forced through a 23 G syringe 20 times to
ensure proper lysis. The resulting cell lysates were kept on ice for
30 min with periodic inversion of the tube. The lysates were mixed
with an equal volume of 80% sucrose in HEPES buffered saline using
needle and syringe. 1 ml of lysate in 40% sucrose was transferred to a
14 × 89mmUltra-clearcentrifuge tube (Beckman Coulter) and overlaid
with 6.5 ml of 30% sucrose followed by 3.5 ml of 5% sucrose in HEPES-
buffered saline. The sample was centrifuged in a Sorvall R Discovery Ul-
tracentrifuge (ThermoScientiﬁc, Carlsbad, USA) with a TH641 rotor at
4 °C for 20 h at 187.813 g to isopycnically separate the membranes.
After ultracentrifugation 1 ml fractions of the gradient were collected.
40 μl of each fraction was subjected to Western Blot analysis as
described above.
3. Results
3.1. Overview
FAPα is a cell surface protease, speciﬁcally expressed byCAFs in solid
tumors. Although it remains elusive how FAPα exerts its functions in
progression of these tumors it's evident, that a variety of different
downstream pathways are involved [4]. There is increasing evidence
of proteases being involved in protein complex formation [14–16]. We
aimed at a holistic overview of the FAPα interactome and therefore ap-
plied the QUICK approach [18] using the CAF-derived cell line CT5.3. An
overviewof the experimentalworkﬂow for theQUICK screen is present-
ed in Fig. 1a. Interaction partners were validated by anti-FAPα IP and
complementary reverse IPs of selected putative interaction partners.
We also proved that association with FAPαwas independent of its stoi-
chiometric binding partner DPPIV. Our interactome results suggested a
recruitment of FAPα to lipid rafts. This was further validated analyzing
the subcellular localization of FAPα using optical sectioning in immuno-
ﬂuorescence microscopy and membrane fractionation studies.
3.2. Protein interaction screening by quantitative immunoprecipitation
combined with knockdown reveals new interaction partners for FAPα
To screen for FAPα interacting proteins we conducted a QUICK
screen [18], which combines SILAC, RNAi-mediated knockdown of the
Fig. 1. QUICK screen. A schematic overview of the experimental procedure is shown (A). The interactome of FAPα in CAFs was analyzed by quantitative immunoprecipitation combined
with knockdown (QUICK) to obtain a list of putative FAPα interaction partners. Key to thismethod is depletion of theprotein of interest for control purposes. A stable shRNAknockdownof
FAPαwas obtained in CT5.3 CAF cell line as shown by Western Blot analysis (B).
Fig. 2.Veriﬁcation of FAPα interaction partners identiﬁed byQUICK using co-immunopre-
cipitation. Equal volumes of cell lysate were immunoprecipitated using an anti-FAPα an-
tibody and an isotype control. A lysate volume corresponding to 5% of the IP-input was
also loaded as a control. Selected FAPα interaction partners identiﬁed in the QUICK screen
were veriﬁed byWestern Blotting.
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protein interactions under endogenous conditions.
Key to the QUICK assay is a sufﬁcient depletion of the protein of in-
terest for control purposes. Using a lentiviral transfection systemwe in-
troduced a stable shRNA knockdown of FAPα in the CT.5.3 human colon
CAF cell line. FAPα expression was almost completely abolished in
CT5.3shFAPα cells compared to CT5.3shctrl cells as shown by western
blot analysis (Fig. 1b).
For the QUICK approach, immunoprecipitation of FAPα was per-
formed in equal amounts of heavy labeled CT5.3shctrl and light labeled
CT5.3shFAPα cell lysates using an anti-FAPα antibody. Immunoprecipi-
tates of both conditions were combined and subjected to LC-MS/MS
analysis.We aimed to identify FAPα interaction partners with high con-
ﬁdence and therefore performed the QUICK experiment in ﬁve repli-
cates. FAPα was signiﬁcantly enriched in all replicates with a mean
fold change (log2 of enrichment in QUICK experiment) of 4.18 com-
pared to the knockdown situation (Table 1). In addition to FAPα we
identiﬁed 10 proteins that were signiﬁcantly enriched in the QUICK
Co-IP experiments (p-value b 0.01). These proteins were considered
as putative FAPα interaction partners (Table 1). Remarkably, FAPα
was identiﬁedwith a sequence coverage of over 30% in all ﬁve replicate
experiments (data not shown), highlighting the abundant presence of
the bait in the immunoprecipitate. High sequence coverage was also
reached for most of the putative interaction partners as evident by pep-
tide mapping (Supplementary Fig. S1).
The known stoichiometric binding partner of FAPα, dipeptidyl pep-
tidase IV (DPPIV) featured prominently among the enriched proteins in
the immunoprecipitates. This proves that our lysis conditions preserved
native FAPα interaction partners while achieving sufﬁcient solubiliza-
tion of FAPαwith its transmembrane domain.
Fig. 3. Veriﬁcation of FAPα interaction partners identiﬁed by QUICK using reverse
co-immunoprecipitation. Equal volumes of cell lysate were immunoprecipitated using
either anti-caveolin-1 (A), stomatin (B) or erlin-2 (C) antibody and an isotype control.
A lysate volume corresponding to 5% of the IP-input was also loaded as a control.
FAPα co-immunoprecipitation was veriﬁed by Western blotting using the indicated
antibodies.
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complimentary reverse co-IP
In order to validate the putative FAPα interaction partners we per-
formed a large scale Western Blot analysis of FAPα immunocomplexes
isolated from CT5.3wt cells. We probed eight of the identiﬁed interac-
tion partners (Fig. 2), namely DPPIV, adenosine deaminase (ADA),
caveolin-1, erlin-2, prohibitin, stomatin, Thy-1 membrane glycoprotein
(Thy1), and the bait protein FAPα itself. The Western Blot analysis re-
vealed a speciﬁc signal for all these proteins upon FAPα co-immunopre-
cipitation. This underscores that the QUICK protocol and performing the
co-IP screen with ﬁve replicates, reveal interacting proteins with high
conﬁdence.
We also established reverse co-IPs for several identiﬁed interaction
partners (Fig. 3a–c): immunoprecipitation of caveolin-1, erlin-2, and
stomatin revealed FAPα as an interaction partner. This validates
caveolin-1, erlin-2, and stomatin as bona ﬁde FAPα interaction partners.
3.4. FAPα interaction partners are independent of DPPIV
DPPIV is a known stoichiometric binding partner of FAPα. Various
interaction partners are described for DPPIV. Among those is adenosinedeaminase (ADA) [29] which we validated to co-immunoprecipitate
with FAPα (Table 1 and Fig. 2). Since FAPα and DPPIV are known to
form heterodimers, we considered the possibility that the aforemen-
tioned putative FAPα interaction partners rather bind to DPPIV than
to FAPα. Immunoprecipitation of FAPα together with its endogenous
interaction partner DPPIV might result in co-immunoprecipitation of
DPPIV binding partners, which would be falsely classiﬁed as interacting
with FAPα. To investigate this situation, we performed DPPIV co-
immunoprecipitation analyses and probed co-immunoprecipitation of
selected, putative FAPα interaction partners (Fig. 4a). We focused on
those FAPα interaction partners that were previously validated by im-
munoblotting (Fig. 2). We initially proved that our lysis and immuno-
precipitation conditions were suitable for the co-immunoprecipitation
of the known DPPIV binding partner ADA. As expected, ADA co-
immunoprecipitated with DPPIV (Fig. 4a). In contrast, stomatin, erlin-
2, prohibitin, and Thy1 did not co-immunoprecipitate with DPPIV in
substantial amounts (Fig. 4a). Therefore we exclude that DPPIV medi-
ates co-immunoprecipitation of these proteins with FAPα. However,
we noticed a slight co-immunoprecipitation of the membrane protein
caveolin-1with DPPIV (Fig. 4a). In order to fully exclude DPPIV-mediat-
ed interaction of caveolin-1 to FAPα we established a transient DPPIV
knockdown in CT5.3 cells using siRNA.We achieved a substantial reduc-
tion of DPPIV expression in CT5.3 cells (Fig. 4b). Using this cell system
we performed FAPα co-immunoprecipitation analysis (Fig. 4c). As an-
ticipated, co-immunoprecipitation of ADA with FAPα was reduced in
the DPPIV knock-down situation. This ﬁnding underlines that DPPIV
recruits ADA to the FAPα-DPPIV heterodimer. This ﬁnding further
excludes ADA as a direct FAPα interaction partner. In contrast, co-
immunoprecipitation of caveolin-1 with FAPα was not affected by the
absence of DPPIV, hence proving a direct interaction of caveolin-1
with FAPα, independent of DPPIV.
3.5. Membrane distribution of FAPα is predominantly conﬁned to lipid rafts
FAPα is known to be a cell surface protease. In good agreement,most
of the identiﬁed FAPα interaction partners are also annotated as localiz-
ing to the plasma membrane. Yet the plasma membrane is a heteroge-
neous structure composed of different sub-fractions that are deﬁned
by speciﬁc lipid and protein composition. Several FAPα interaction part-
ners, e.g. caveolin-1, typically localize to lipid rafts. Lipid rafts are dy-
namic nanoscale membrane structures, composed of speciﬁc protein
assemblies and enriched in sphingolipids. Lipid rafts comprise a pletho-
ra of lipid–lipid, protein–lipid, and protein–protein interactions [27].
The lipid raft localization of several FAPα interaction partners raised
our interest to investigatewhether FAPα also localizes to lipid raft struc-
tures.We performed sucrose density ultracentrifugation analysis to iso-
late lipid raft fractions from CAF cell lysates. Because of the high content
of cholesterol and sphingolipids, the overall density of lipid raft proteins
is lower, compared to other plasmamembrane proteins, therefore lead-
ing to differential fractionation in a sucrose gradient. Caveolin-1 is a
well-established and widely used lipid raft marker [32]. Accordingly,
we used caveolin-1 to distinguish lipid raft positive fractions. Fig. 5a
shows that caveolin-1 is found in low density fractions (fractions
three–ﬁve) of the sucrose gradient; in line with its localization to lipid
rafts. FAPα co-localizes to the caveolin-positive, low-density fractions.
This ﬁnding strongly indicates lipid raft localization of FAPα. It also sub-
stantiates interaction of caveolin-1 and FAPα.
We aimed to further investigate the subcellular localization of FAPα
by immunoﬂuorescence microscopy. Using Alexa ﬂuorophore coupled
choleratoxine B we labeled GM1 ganglioside which is enriched in lipid
rafts of CT5.3wt cells. We used a monoclonal mouse derived antibody
to stain for FAPα and validated antibody speciﬁcity in immunoﬂuores-
cence staining (Supplementary Fig. S2). To probe localization of FAPα
in lipid rafts, we performedmicroscopic analysis including optional sec-
tioning of the sample. Overlay of both GM1 lipid raft marker and FAPα
staining reveals co-localization of both to a great extent (Fig. 5b). This
Fig. 4. FAPα interaction partners are independent of DPPIV. To prove whether putative interaction partners bind to FAPα independent of its stoichiometric binding partner DPPIV, DPPIV
co-immunoprecipitation analyseswere performed (A). Cell lysateswere immunoprecipitated using an anti-DPPIV antibody and an isotype control. A lysate volume corresponding to 5% of
the IP-input was also loaded as a control. DPPIV co-immunoprecipitation was tested by Western blotting using the indicated antibodies. To further exclude DPPIV dependence in FAPα
interaction with caveolin-1 a siRNA mediated DPPIV knockdown was established (B). Equal volumes of cell lysate, both with and without DPPIV knockdown, were immunoprecipitated
using an anti-FAPα antibody and co-immunoprecipitated proteins were tested by Western blot analysis.
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of the membrane, leading to a conﬁned localization of FAPα within
the membrane.
3.6. FAPα interacts with caveolin-1 and stomatin in lipid rafts of cancer-
associated ﬁbroblasts
We aimed to further corroborate that FAPα interaction partners are
also recruited to lipid rafts by investigating cellular localization of FAPα
and its newly identiﬁed interaction partners. Caveolin-1 is known to lo-
calize to lipid rafts and to act as a scaffold for the recruitment of further
proteins to lipid rafts [30]. Optional sectioning of immunoﬂuorescence
stainings of CT5.3wt cells shows abundant co-localization of caveolin-
1 and FAPα staining, thereby further conﬁrming the interaction be-
tween caveolin-1 and FAPα as well as conﬁrming recruitment of FAPα
to the lipid raft fraction of the cell membrane (Fig. 6a). Similarly, optical
sectioning supports co-localization of FAPα and stomatin which is also
known to be conﬁned to lipid raft subdomains of the plasmamembrane
(Fig. 6b). Together, these ﬁndings are suggestive of FAPα being embed-
ded in lipid-raft speciﬁc higher order protein complexes.
3.7. Lipid raft localized FAPα is recruited to invadopodia
Invadopodia are F-actin-rich protrusions of the cell membrane
involved in reshaping the extra cellular matrix [34] and impacting the
migration of cancer cells [35]. Lipid rafts are necessary for the formation
of invadopodia.We used immunoﬂuorescence analysis to investigate whether FAPα
localizes into invadopodia. CAFs show typical stress ﬁbers spanning the
cell body which mainly consist of F-actin. F-Actin is visualized by
rhodamin-coupled phalloidin (Fig. 7a). Already in unstimulated condi-
tion some F-actin was present in rosette like structures corresponding
to invadopodia. FAPαwas co-localizing with these structures.
To further induce invadopodia in CT5.3 cells, short-term treatment
with the protein kinase C (PKC) activator PMA was performed [28].
This lead to an increased number of invadopodia corresponding
rosette-like structures which were co-localizing with FAPα (Fig. 7b).
This conﬁrms that FAPα is not only present in the lipid raft part of the
membrane but also recruited into invadopodia likely to impact the ma-
trix remodeling properties of these structures.
4. Discussion
FAPα is expressed in the stromal microenvironment of most solid
tumors. This speciﬁc expression proﬁle is exploited for therapeutic
strategies, including FAPα-activated prodrugs [4] and tumor vaccines
[36]. To better understand the underlying biology of FAPα, we per-
formed a global analysis of the FAPα interactome using the QUICK
approach.
4.1. The cell surface protease FAPα participates in protein complex
formation
Although there is increasing evidence that proteases interact with
other proteins in a non-catalytic manner (14, 15, 16), our study is one
Fig. 5. FAPα localizes to lipid rafts. Sucrose density ultracentrifugation was performed to validate FAPα enrichment in lipid rafts (A). Equal volumes of all fractionswere loaded and tested
byWestern Blot analysis using the indicated antibodies. Caveolin-1was used as a positive control for the lipid raft fraction of themembrane. TfR (transferrin receptor)was used as non-raft
marker. FAPα localizationwas further validated by immunoﬂuorescence combinedwith ApoTome optical sectioning (B). Alexa Fluorophore 555 coupled choleratoxine Bwas used to label
lipid raft enriched GM1 gangliosid. Images were acquired by ApoTome optical sectioning. Representative images are shown.
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ased, proteomic techniques. We have successfully identiﬁed novel
FAPα interaction partners, in addition to the stoichiometric binding
partner DPPIV. Immunoblotting validated most of the QUICK results as
well as highlighting that the newly established FAPα interactome isFig. 6. FAPα co-localizes with caveolin-1 and stomatin in deﬁned membrane regions. FAPα co-
ﬁrmed by immunoﬂuorescence combined with ApoTome optical sectioning. Representative imindependent of DPPIV. Immunoﬂuorescence microscopy further
proofed colocalization of FAPαwith selected, novel interaction partners.
Generally, our results underline applicability of the QUICK method for
cell surface proteases while highlighting non-catalytic properties form
an essential aspect of protease biology.localization with caveolin-1 (A) and stomatin (B) under endogenous conditions was con-
ages are shown.
Fig. 7. FAPα localizes to invadopodia. Cells were treated either with DMSO control (A) or with PMA (B) for 1 h. F-Actinwas visualizedwith rhodamine-coupled phalloidin. Arrows indicate
F-actin enriched rosette like structures corresponding to invadopodia both in unstimulated (A) and stimulated (B) condition. Images were acquired by ApoTome optical sectioning.
Representative images are shown.
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localization
Lipid raft localization featured as the most enriched GO term (Supp.
Fig. 1) in the QUICK-derived FAPα interactome. Based on this observa-
tion, we hypothesized that FAPα is recruited into lipid rafts rather
than being randomly distributed across the cell surface. Our hypothesis
was veriﬁed by complementary experimental approaches, including
immunoﬂuorescence analysis showing localization of FAPα with a
lipid raft marker and by density gradient fractionation of membranes,
which revealed FAPα presence predominantly in the lipid raft fraction.
Lipid rafts are dynamic membrane structures with a distinct lipid
composition, whose speciﬁc chemical properties harbor a variety of
protein–protein interactions [27]. Among these are receptors involved
in signal transduction [37], modulators of the cytoskeleton, [38] and
proteases [39]. Based on these complex protein networks, lipid raftsFig. 8.Overviewof the FAPα interactome.We conclude that FAPα is conﬁned to the lipid raft dom
Their localization is based on GO term annotation for cellular compartment. ADA (adenosin
glycoprotein).mediate a plethora of biological processes. Among these are domain
mediated membrane trafﬁcking and the reshaping of the cellular archi-
tecture to form invadopodia and podosomes.
In addition to caveolin-1, several other newly identiﬁed FAPα inter-
action partners also localize mainly to lipid rafts (Fig. 6). Among these
are stomatin, erlin-2, and prohibitin which all belong to the stomatin
protein family. Members of this protein family are commonly found in
lipid raft structures [40,41] and share a common domain known as
SPFH (stomatin, ﬂotillin, prohibitin, HﬂC/K) [42]. Our immunoﬂuores-
cence and density gradient membrane fractionation analysis validated
co−localization of FAPα and stomatin in lipid rafts. Overall, robust in-
teraction proteomics by QUICK together with suitable protein annota-
tion has allowed us to convert the newly identiﬁed FAPα interactome
into a novel aspect of FAPα biology.
Lipid rafts are fundamentally involved in the formation of
invadopodia. Indeed, previous work has indicated that FAPα localizesainswithin themembrane. Identiﬁed and validated FAPα interaction partners are shown.
deaminase), Erlin (erlin-2); PHB (prohibitin), Stom (stomatin), Thy1 (Thy-1 membrane
Table 1
Putative FAPα interaction partners.
Uniprot ID Name p-Value Fc-value Error-range
ADA_HUMAN Adenosine deaminase b0.01 4.39 1.28
CAV1_HUMAN Caveolin-1 b0.01 2.62 0.71
DPP4_HUMAN Dipeptidyl peptidase 4 b0.01 3.68 0.74
ERLN2_HUMAN Erlin-2 b0.01 2.65 1.39
STOM_HUMAN Erythrocyte band 7 integral
membrane protein
(stomatin)
b0.01 3.97 1.75
PHB_HUMAN Prohibitin b0.01 1.89 0.59
PHB2_HUMAN Prohibitin-2 b0.01 1.77 1.16
SEPR_HUMAN Prolyl endopeptidase FAPα b0.01 4.18 0.91
RBM4_HUMAN RNA-binding protein 4 b0.01 2.30 1.25
THY1_HUMAN Thy-1 membrane
glycoprotein
b0.01 3.73 1.98
TM109_HUMAN Transmembrane protein 109 b0.01 3.71 2.08
p-Value: two-sided T-test, Fc: fold-change-value. log2 (Fap-wt/Fap shRNA), all proteins
observed in at least 4 of 5 replicate experiments.
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not express FAPα in vivo [43]. We could show in these study that
FAPα also localizes to invadopodia in CAFs which physiologically ex-
press FAPα. It was shown recently that pancreatic CAFs are able to
form functional, matrix-degrading invadopodia that mediate migration
of pancreatic cancer cells [44]. FAPα is known to act as a collagenase/
gelatinase [4]. Since we could show invadopodia localization for FAPα
this suggests that this protease contributes to the focal matrix-
degrading capability of stromal invadopodia.
4.3. FAPα interaction with caveolin-1
Among the identiﬁed interaction partners for FAPα, caveolin-1 is of
particular interest. Caveolin-1 is a ubiquitously expressed scaffolding
protein that is enriched in lipid rafts [45]. Caveolin-1 is a small protein
with a single intramembrane domain. However, it does not cross the
plasma membrane and typically comprises of an N- and a C-terminal
cytoplasmic domain. The intramembrane domain serves to tether
caveolin-1 to the cytoplasmic side of the plasma membrane [46,47]. At
the same time, it has been suggested that caveolin-1 expressed by anti-
gen presenting cells, interacts with DPPIV in a way that requires the N-
terminal domain of caveolin-1 to cross the plasma membrane, thus
being re-localized to the extracellular side of the plasma membrane
[48,49]. To further investigate the interaction of FAPα and caveolin-1,
we expressed FLAG-tagged caveolin-1 in FAPα deﬁcient CT5.3 ﬁbro-
blasts. We then co-cultured these cells with wild-type CT5.3 ﬁbroblasts
and performed co-immunoprecipitation of FAPα. FLAG-tagged
caveolin-1, stemming from FAPα deﬁcient CT5.3 ﬁbroblasts, did not
co-immunoprecipitate with FAPα (data not shown), thus suggesting
that the interaction between FAPα and caveolin-1 happens within the
same cell and does not require re-organization of the caveolin-1
localization.
Caveolin-1 physically interacts with a large number of proteins via
the caveolin scaffold domain (CSD) thereby recruiting them into lipid
rafts and modulating their activity [50]. Among these are proteins in-
volved in mitogenic signaling [51], apoptosis [52], cancer progression
and metastasis [53,54] and vascular diseases [55]. Many of these pro-
teins share an aromatic-rich caveolin bindingmotif (CBM) фXфXXXXф,
фXXXXфXXф or фXфXXXXфXXф, where X is a variable amino acid and
ф denotes aromatic residues. Although this sequence motif is present in
FAPα (F111VYLESDY118, Y164VYQNNIY171), it is found in the FAPα
ectodomain. As such, it is unlikely that the FAPα/caveolin-1 interaction
is mediated by these sequence features. In fact, further reports indicate
caveolin-1 interactions mediated by other sequence motifs [56].
Interestingly, stromal expression of caveolin-1 or FAPα correlates
with disease severity in several types of solid tumors. Caveolin-1 ex-
pression in CAFs is a positive prognostic marker for survival in gastriccancer [57,58], prostate cancer [59,60] and lung cancer [61]. In these
cancer entities reduced caveolin-1 expression correlates with increased
invasion and metastatic burden. FAPα expression also correlates with
invasion and clinical outcome in this cancer entities [62,63]. These ﬁnd-
ings highlight that the contribution of the FAPα-caveolin axis to tumor-
igenesis merits further investigation.
FAPα itself has become a widely investigated target for antitumor
therapies, including vaccination strategies [64], pro-drug conversion
[65] and target speciﬁc delivery of cytotoxic drugs [66]. Knowledge
about its precise subcellular localization and complex formation may
guide optimization of the aforementioned strategies. Further therapeu-
tic approaches under development aim at inhibiting the proteolytic
activity of FAPα. Yet clinical testing in patients with metastatic, non-
resectable colorectal cancer yielded only minimal clinical beneﬁt [67].
It requires further investigation whether enzymatic or non-enzymatic
functions of FAPα should be the target of further therapeutic develop-
ments. This study investigated the interaction of FAPα with several
other cell surface exposed proteins and therefore might suggest new
therapeutic opportunities involving these FAPα interaction partners.
In summary, we used QUICK as a robust approach for one of the ﬁrst
attempts to proteomically deﬁne the interactome of a cell-surface pro-
tease. We identiﬁed and validated novel interaction partners for the
CAF marker FAPα. Our studies revealed interaction of FAPα with lipid
raft localized proteins. We further showed recruitment of FAPα to
lipid rafts (Fig. 8). These ﬁndings provide a new perspective on the biol-
ogy of this important protease and link FAPα to the function of lipid
rafts in the tumor microenvironment.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2015.07.013.
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